Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Osteoporosis
How do you manage hepatotoxicity thought to be related to Romosozumab use?
Have you seen liver toxicity associated with Romosozumab?
Related Questions
What is your approach to bisphosphonate use in patients with advanced chronic kidney disease and osteoporosis?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
Do you start bisphosphonates after tapering off menopausal hormone therapy to prevent the rapid decline of bone mineral density?
Is there a maximum duration for raloxifene use?
How soon after a fracture would it be safe to start anti-resorptive therapy?
How should we interpret DXA scans in patients with Ankylosing Spondylitis who have ankylosis of the spine?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
How do you approach management of bone marrow involvement in sarcoidosis?
Is it safe to continue azathioprine in a patient with severe bilateral panuveitis (thought to be related to sarcoidosis) and benign ethnic neutropenia, given worsening neutropenia since starting the medication, or should an alternative immunosuppressive agent be considered?
